Interactive Features

Test Your Knowledge

Quiz: Does Ropeginterferon Show Clinical Benefit for MPN?

09/27/2021

True or false: Ropeginterferon, a novel agent also used to treat polycythemia, showed clinical benefit as an effective drug with less frequent doses and less side effects in the treatment of MPN.

True or false: Ropeginterferon,...

09/27/2021

Oncology

Test Your Knowledge

Quiz: Is Fedratinib Beneficial for Patients with MF?

09/23/2021

True or false: First-line fedratinib does not improve PFS in patients with MF.

True or false: First-line...

09/23/2021

Oncology

Test Your Knowledge

Which Oral JAK2 Inhibitor Improves PFS in MF?

08/31/2021

Study findings suggest that ______, an oral JAK2 inhibitor, significantly improves PFS versus placebo as a first-line treatment in patients with MF).

Study findings suggest that...

08/31/2021

Oncology

Test Your Knowledge

Quiz: Azacitidine With or Without Venetoclax for Antecedent MDS/MPNs

06/28/2021

True or False: Venetoclax plus azacitidine led to higher rates of complete remission, a longer DoR, and median OS than azacitidine monotherapy in treatment-naïve patients with therapy-related myeloid neoplasms and antecedent MDS or MPNs.

True or False: Venetoclax plus...

06/28/2021

Oncology

Test Your Knowledge

Quiz: Patient Characteristics Tied to Outcomes in tMN or A-MDS/MPNs

06/25/2021

Patients with tMN or A-MDS/MPNs may have poor outcomes due to which of the following characteristics?

Patients with tMN or A-MDS/MPNs...

06/25/2021

Oncology

Test Your Knowledge

Quiz: Do Experts Recommend Serum PCT as Biomarker in Ph-Negative MPNs?

04/20/2021

True or false: Experts recommend the use of serum procalcitonin as a disease biomarker in patients with MPNs.

True or false: Experts recommend...

04/20/2021

Oncology

Test Your Knowledge

Quiz: Combining Azacitidine With Eprenetapopt for the Treatment of TP53-Mutant MDS

02/19/2021

True or False: The addition of azacitidine to eprenetapopt led to significantly low rates of response and remission in a study of patients with TP53-mutant MDS and oligoblastic AML.

True or False: The addition of...

02/19/2021

Oncology

Test Your Knowledge

Quiz: Is There a Link Between Serum Ferritin Level and Fibrosis in Older Patients With MF?

02/19/2021

Is there a significant link between serum ferritin level and fibrosis in older patients with MF?

Is there a significant link...

02/19/2021

Oncology

Test Your Knowledge

Quiz: HCT Tied to Extended Survival, Early Death in Patients With MF

01/28/2021

True or False: A long-term survival advantage has been demonstrated with allogeneic HCT in certain patients with MF, at the expense of possible early death.

True or False: A long-term...

01/28/2021

Oncology

Test Your Knowledge

Quiz: Which Combo Regimen Showed Promise for Advanced MPN in the PHAZAR Trial?

01/18/2021

Which combo regimen did the PHAZAR trial confirm as being well-tolerated with comparable safety for patients with advanced-phase MPN/post-MPN AML?

Which combo regimen did the...

01/18/2021

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology